RxDoctor Payments Data

Stephen Johns, MD

Physical Medicine & Rehabilitation · Gulfport, MSNPI 1881709053

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by UCB, Inc. at 47.2% of the total. That places this record below the midpoint for physical medicine & rehabilitation clinicians in MS, where the typical reported total is $1,133.

$59in general payments, 2019–2025

Across 3 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$28
  • Pfizer$19
  • Sunovion Pharmaceuticals Inc.$13

What the payments were for

  • Food & beverage$59100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.1$28
Pfizer1$19
Sunovion Pharmaceuticals Inc.1$13

How this compares

$59 in reported general payments places this provider in the 15th percentile of 21 physical medicine & rehabilitation providers in Mississippi.

See all physical medicine & rehabilitation providers in Mississippi

Medicare billing

Part B allowed, 2024
$426,607
Medicare patients
980
Services billed
5,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban715$214,948
Humira PenAdalimumab12$87,774
JanuviaSitagliptin Phosphate200$56,747
XareltoRivaroxaban183$51,289
JardianceEmpagliflozin144$44,683
EntrestoSacubitril/Valsartan126$42,643
XifaxanRifaximin27$41,145
MyrbetriqMirabegron142$37,095
LinzessLinaclotide60$34,404
Risperdal ConstaRisperidone Microspheres26$34,117
NuedextaDextromethorphan Hbr/Quinidine32$33,875
Potassium Chloride661$27,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$21,290
Pantoprazole Sodium619$18,536
InvokanaCanagliflozin54$16,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$214,948715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 21 physical medicine & rehabilitation providers in Mississippi.

Other physical medicine & rehabilitation in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →